However, in a recent study by Bonazzi et al., whole-genome sequencing was performed on endometrial cancer PDXs with four molecular subtypes, (e.g., POLE mutations, mismatch-repair deficiency (MMRd), copy number high/TP53 mutations, and no specific molecular profile). This evidence concerns the gene TP53 and endometrial cancer.